Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Comparison of ophthalmic beta-blocking agents.

T S Lesar1

  • 1Albany Medical Center Hospital, Department of Pharmaceutical Services, NY 12208.

Clinical Pharmacy
|June 1, 1987
PubMed
Summary

Betaxolol and levobunolol effectively reduce intraocular pressure in glaucoma patients, similar to timolol. Betaxolol offers potential safety benefits for those with reactive airway disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epoetin in the 'untransfusable' anaemic patient: a retrospective case series and systematic analysis of literature case reports.

Transfusion medicine (Oxford, England)·2014
Same author

Antiretroviral medication errors for patients with HIV infection.

The AIDS reader·2003
Same author

Antiretroviral prescribing errors in hospitalized patients.

The Annals of pharmacotherapy·2000
Same author

Errors in the use of medication dosage equations.

Archives of pediatrics & adolescent medicine·1998
Same author

Medication-prescribing errors in a teaching hospital. A 9-year experience.

Archives of internal medicine·1997
Same author

Comparison of programs for preventing drug-nutrient interactions in hospitalized patients.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1997

Area of Science:

  • Ophthalmology
  • Pharmacology

Background:

  • Glaucoma management involves reducing intraocular pressure (IOP).
  • Beta-adrenergic blocking agents are a cornerstone of glaucoma treatment.
  • Timolol was the first ophthalmic beta-blocker used for glaucoma.

Purpose of the Study:

  • To review the chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and administration of betaxolol and levobunolol.
  • To compare these agents with timolol for treating primary open-angle glaucoma (POAG) and ocular hypertension (OHT).

Main Methods:

  • Review of existing literature, including double-blind comparative trials.
  • Analysis of data on efficacy, safety, and dosing of betaxolol, levobunolol, and timolol.
  • Comparison of cardioselective (betaxolol) versus nonselective (levobunolol) beta-adrenergic blockade.

Main Results:

  • Betaxolol and levobunolol demonstrate efficacy in reducing IOP by 15-35%, comparable to timolol.
  • Betaxolol has a higher incidence of local ocular adverse reactions but less systemic blockade, potentially benefiting patients with reactive airway disease.
  • Levobunolol shows similar efficacy and systemic effects to timolol, with possible longer duration allowing once-daily dosing.

Conclusions:

  • Betaxolol and levobunolol are effective alternatives to timolol for managing POAG and OHT.
  • Betaxolol may offer a safety advantage in specific patient populations due to its cardioselectivity.
  • Further research is needed to fully elucidate the long-term benefits and drawbacks of betaxolol and levobunolol.

Related Experiment Videos